Fort Worth, Texas, United States The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Fort Worth.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Health Care, Clinical Trials. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Lantern Pharma, Incysus Therapeutics, 410 Medical The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
This organization was formed by Aaron Fletcher. Besides them, we counted 5 critical employees of this fund in our database.
Considering the real fund results, this VC is 50 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. The important activity for fund was in 2019.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Bios Partners, startups are often financed by UT Horizon Fund, Technium Partners, Tech Coast Angels. The meaningful sponsors for the fund in investment in the same round are DEFTA Partners, KdT Ventures, Kairos Ventures. In the next rounds fund is usually obtained by WakeMed Health & Hospitals, Venture Capital Multiplier Fund, U.S. Department of Defense.
Related Funds
| Fund Name | Location |
| Arnel Capital Management | - |
| Atop Capital | - |
| Ayer Capital Management | California, San Francisco, United States |
| Beijing Runda Huanke Investment | Beijing, Beijing, China |
| Belt Road Capital Management | Cambodia, Phnom Penh |
| Bespoke Strategies | - |
| C-III Capital Partners | - |
| CSL | Australia, New South Wales, Parkville |
| CVC2 | - |
| Feizhu Zichan | - |
| Galois Capital | California, San Francisco, United States |
| Hillcrest Management | Milford, New Hampshire, United States |
| Medical Technologies Innovation Asia | China, Hong Kong, Hong Kong Island |
| Regenerative Medicine Minnesota | Minnesota, Minnesota City, United States |
| Synergia Capital Partners | Netherlands, Utrecht, Veenendaal |
| Tech Wildcatters | Dallas, Texas, United States |
| Three Six Zero | California, Los Angeles, United States |
| Zhejiang Silicon Paradise Asset Management Group | China, Hangzhou, Zhejiang |
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ONL Therapeutics | $15M | 08 Mar 2023 | Ann Arbor, Michigan, United States | ||
Opus Genetics | $19M | 22 Sep 2021 | Raleigh, North Carolina, United States | ||
ONL Therapeutics | $46M | 22 Dec 2020 | Ann Arbor, Michigan, United States | ||
Azitra | $17M | 15 Oct 2020 | Connecticut, United States | ||
Actuate Therapeutics | $6M | 12 Nov 2019 | Fort Worth, Texas, United States | ||
Azitra | $14M | 15 Oct 2019 | Connecticut, United States | ||
Trefoil Therapeutics | $28M | 16 Jul 2019 | San Diego, California, United States | ||
Lung Therapeutics | $36M | 04 Jun 2019 | Austin, Texas, United States | ||
Actuate Therapeutics | $21M | 17 May 2019 | Fort Worth, Texas, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ONL Therapeutics | $15M | 08 Mar 2023 | Ann Arbor, Michigan, United States | ||
Opus Genetics | $19M | 22 Sep 2021 | Raleigh, North Carolina, United States | ||
ONL Therapeutics | $46M | 22 Dec 2020 | Ann Arbor, Michigan, United States | ||
Azitra | $17M | 15 Oct 2020 | Connecticut, United States | ||
Actuate Therapeutics | $6M | 12 Nov 2019 | Fort Worth, Texas, United States | ||
Azitra | $14M | 15 Oct 2019 | Connecticut, United States | ||
Trefoil Therapeutics | $28M | 16 Jul 2019 | San Diego, California, United States | ||
Lung Therapeutics | $36M | 04 Jun 2019 | Austin, Texas, United States | ||
Actuate Therapeutics | $21M | 17 May 2019 | Fort Worth, Texas, United States |
